The Muscle Tissue/Cell Culture/Diagnostics Core for this Wellstone Muscular Dystrophy Cooperative Research Center is a multifaceted laboratory that serves as a local and a national resource for muscular dystrophy research. There are two major goals of the Core. First, the Core will maintain and continue to grow the Repository of skeletal muscle biopsies and cell cultures established during the first five years of funding. Among the existing muscle biopsies are more than 1000 muscular dystrophy samples that include dystrophinopathies (Duchenne and Becker muscular dystrophy), limb-girdle muscular dystrophies, and congenital muscular dystrophies. More than 125 patients (primarily muscular dystrophy patients) have undergone skin biopsies to establish fibroblast cultures in the Repository. We will accrue new specimens into the Repository from a variety of sources: diagnostic muscle biopsies, therapeutic surgical procedures, endomyocardial biopsies, heart explants, skin biopsies, and autopsies. Patients with genetically defined muscular dystrophies are recruited to undergo biopsies in order to maintain a widely representative spectrum of muscular dystrophy diagnoses. Well-characterized tissues and cells from the Core are made available to research investigators at lowa and other academic centers. The second goal of the Core is to provide specialty diagnostic resources unavailable in clinical laboratories. This includes western blots from skeletal muscle as well as on-cell westerns and nuclear morphology assays in cultured cells. The Core facilitates development of new diagnostic tests for transfer to the clinical laboratory, and serves as a post-intervention biopsy evaluation resource for investigators conducting clinical trials. Thus, the Muscle Tissue/Cell Culture/Diagnostics Core maintains a vital resource of muscular dystrophy tissues and cell cultures, provides a critical diagnostic link in expanding the number of patients with specific, molecular diagnoses, and serves as a national biopsy testing resource for clinical trials in muscular dystrophy patients.

Public Health Relevance

The Muscle Tissue/Cell Culture/Diagnostics Core assists in making accurate diagnoses for muscular dystrophy patients. With this information, physicians are better able to provide genetic counseling, prognostic information, and treatment options for their patients. Tissue and cell culture resources from the Core support basic and clinical research that will lead to improved therapeutic interventions for this group of rare genetic diseases

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1-SRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Iowa
Iowa City
United States
Zip Code
Bönnemann, Carsten G; Wang, Ching H; Quijano-Roy, Susana et al. (2014) Diagnostic approach to the congenital muscular dystrophies. Neuromuscul Disord 24:289-311
Inamori, Kei-ichiro; Willer, Tobias; Hara, Yuji et al. (2014) Endogenous glucuronyltransferase activity of LARGE or LARGE2 required for functional modification of ?-dystroglycan in cells and tissues. J Biol Chem 289:28138-48
Chauveau, Claire; Bonnemann, Carsten G; Julien, Cedric et al. (2014) Recessive TTN truncating mutations define novel forms of core myopathy with heart disease. Hum Mol Genet 23:980-91
Wallace, Stephanie E; Conta, Jessie H; Winder, Thomas L et al. (2014) A novel missense mutation in POMT1 modulates the severe congenital muscular dystrophy phenotype associated with POMT1 nonsense mutations. Neuromuscul Disord 24:312-20
Willer, Tobias; Inamori, Kei-Ichiro; Venzke, David et al. (2014) The glucuronyltransferase B4GAT1 is required for initiation of LARGE-mediated ?-dystroglycan functional glycosylation. Elife 3:
Crockett, Cameron D; Ruggieri, Alessandra; Gujrati, Meena et al. (2014) Late adult-onset of X-linked myopathy with excessive autophagy. Muscle Nerve 50:138-44
Goddeeris, Matthew M; Wu, Biming; Venzke, David et al. (2013) LARGE glycans on dystroglycan function as a tunable matrix scaffold to prevent dystrophy. Nature 503:136-40
Cirak, Sebahattin; Foley, Aileen Reghan; Herrmann, Ralf et al. (2013) ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies. Brain 136:269-81
Yang, Amy C; Ng, Bobby G; Moore, Steven A et al. (2013) Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular dystrophy. Mol Genet Metab 110:345-51
Stevens, Elizabeth; Carss, Keren J; Cirak, Sebahattin et al. (2013) Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of *-dystroglycan. Am J Hum Genet 92:354-65

Showing the most recent 10 out of 47 publications